Krystal Biotech, Inc. KRYS
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 2.46% | 8.64% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.46% | 8.64% | |||
| Cost of Revenue | 1.80% | -4.08% | |||
| Gross Profit | 2.50% | 9.47% | |||
| SG&A Expenses | -2.84% | -1.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.97% | -0.27% | |||
| Operating Income | 8.81% | 21.28% | |||
| Income Before Tax | 7.55% | 20.17% | |||
| Income Tax Expenses | 105.28% | 2,148.33% | |||
| Earnings from Continuing Operations | -2.08% | 8.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.08% | 8.82% | |||
| EBIT | 8.81% | 21.28% | |||
| EBITDA | 8.05% | 20.92% | |||
| EPS Basic | -2.88% | 8.09% | |||
| Normalized Basic EPS | 6.67% | 19.37% | |||
| EPS Diluted | -2.19% | 7.40% | |||
| Normalized Diluted EPS | 7.01% | 19.16% | |||
| Average Basic Shares Outstanding | 0.82% | 0.67% | |||
| Average Diluted Shares Outstanding | 0.49% | 0.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||